At ACA Pharma, we specialize in fast-track registration and tailored market entry solutions for Asia. Our services include streamlined registration in Macau, Hong Kong, and Singapore for new and innovative drugs, enabling rapid access to the Asian market. Through initiatives like the Asian Patient Access Program (APAP), we provide flexible solutions to meet urgent patient needs and empower originators to swiftly expand sales to unregistered regions worldwide, complementing Macau’s registration pathway and ensuring long-term success through our extensive physician network

• 54 New Drugs Registered; 7 in Submission Process
• Quick Registration in Macau (30-90 Days)
• 100% Registration Success Rate
• No Additional Clinical Trials Required
• Zero Additional Investment Needed

Critical Care Solutions

• Our Critical Care Solutions enable rapid access to pediatric and clinically urgent medications, support fast-track national approvals, and ensure broad media coverage for patient awareness. These services streamline access to life-saving treatments while facilitating market entry for innovative drugs. Learn more about our services.

Our streamlined registration process in Macau ensures that innovative and clinically urgent drugs can swiftly enter the Chinese market, addressing unmet medical needs and delivering life-saving treatments to patients. This approach also facilitates rapid recovery of development investments, empowering originators to achieve impactful market entry with minimal delays.